Sudarshan Pharma Industries Ltd
543828Sudarshan Pharma Industries Ltd's earnings have outrun its stock. EPS grew +47.0% in a year against a +37.8% price move.
Biggest watch item: the P/E sits at the 77th percentile of its own range — the multiple has already done part of the work.
The price is in a confirmed uptrend (12 weeks in) while the P/E sits at the 77th percentile of its own 3-year range. Underneath, the last four quarters read improving — profit +57.1% year on year, and 78% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Sudarshan Pharma Industries Ltd trades at ₹40.0, in a confirmed uptrend and 12 weeks into that stage. That is +30.1% against its own 200-day average. It sits at 100% of a 52-week range of ₹20 to ₹40. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 25 straight weeks.
Today the stock is in a confirmed uptrend — week 12 of stage 2, confirmed. At ₹40.0 it trades +30.1% versus its 200-day average and sits at 100% of its 52-week range (₹20–₹40).
Against the market, two honest reads. Cumulative: over the last 3.3 years the stock moved +539% while the NIFTY 500 moved +63% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 25 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 77th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Sudarshan Pharma Industries Ltd trades at 43.2× P/E, at the pricey end of its own range (77th percentile). Its long-run median P/E is 31.2×, measured across 3.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 43.2× is at the pricey end of its own range (77th percentile), against a long-run median of 31.2× measured over 3.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +47.0% against a +37.8% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +85.2%/yr price move, ~+20.8%/yr came from earnings growth and ~+64.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Sudarshan Pharma Industries Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +39.2% | +15.1% | +29.5% | — |
| Profit | +43.8% | +48.7% | +50.3% | — |
| EPS | +47.0% | +49.6% | +28.2% | — |
| Share price | +37.8% | +85.2% | — | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
57.2/100 — rank 7 of 48 in Trading · 79% evidence confidence
Sudarshan Pharma Industries Ltd scores 57.2 out of 100 against the 48 companies it is compared with in Trading, ranking 7. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 18.6 + 11.2 + 9.5 + 17.9 = 57.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Sudarshan Pharma Industries Ltd reported ₹221 Cr of revenue in the Mar 26 quarter, +36.4% year on year. That is the 4th straight quarter of year-on-year growth. Over 6 years it has compounded at 29.7% a year. The last full year, FY26, came in at ₹703 Cr. The last four reported quarters add to ₹703 Cr.
Sudarshan Pharma Industries Ltd reported ₹221 Cr of revenue in the Mar 26 quarter, +36.4% year on year. That is the 4th straight quarter of year-on-year growth. Over 6 years it has compounded at 29.7% a year. The last full year, FY26, came in at ₹703 Cr. The last four reported quarters add to ₹703 Cr.
FY26 revenue came in at ₹703 Cr (+39.2% on the year), capping 6 years at 29.7% compound. The latest quarter (Mar 26) printed ₹221 Cr, +36.4% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +39.7% growth against the decade's 29.7% — the current year is running faster than its own long-run rate.
→ Revenue grew — did margins hold as it scaled? Next: 9.0% this quarter (−1.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Sudarshan Pharma Industries Ltd's operating margin is 9.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 3.0% to 8.0%. The current quarter is running above every full year in that window.
Sudarshan Pharma Industries Ltd's operating margin is 9.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 3.0% to 8.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 9.0%, −1.0 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 3.0%–8.0%.
🚨 Why the margin moved: operating margin went −0.7 pp year on year while gross margin went −0.2 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins slipped — did that reach the bottom line? Next: profit +57.1% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Sudarshan Pharma Industries Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, +57.1% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹23.0 Cr. The 6-year compound rate is 68.6%. That is 5.0% of the quarter's revenue. The same quarter a year earlier earned ₹7.0 Cr.
Sudarshan Pharma Industries Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, +57.1% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹23.0 Cr. The 6-year compound rate is 68.6%. That is 5.0% of the quarter's revenue. The same quarter a year earlier earned ₹7.0 Cr.
Mar 26 profit was ₹11.0 Cr, +57.1% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹23.0 Cr (+43.8%), and the 6-year compound rate is 68.6%.
Why profit moved: revenue contributed +36.4% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +19.0% vs revenue +39.7%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 78% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 78% of Sudarshan Pharma Industries Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹−2.0 Cr of operating cash against ₹23.0 Cr of profit. After ₹81.0 Cr of capital spending, ₹−83.0 Cr was left as free cash.
FY26: operating cash of ₹−2.0 Cr against reported profit of ₹23.0 Cr, leaving free cash of ₹−83.0 Cr after ₹81.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 78% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 78%: the cash cycle stretched 67 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: conversion is below par and the cash cycle has stretched 67 days — the next section's job is to find where the cash is stuck.
→ So follow the cash to where it goes. Next: the 139-day cycle, in money terms.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Sudarshan Pharma Industries Ltd's cash conversion cycle runs 139 days in FY26, up from 72 days in FY21. Capital spending ran ₹94.0 Cr over the last 3 years. At FY26 sales of ₹703 Cr each day of that cycle holds about ₹1.9 Cr, so roughly ₹268 Cr sits inside the business at any moment.
FY26: debtors at 121 days, inventory at 129 days — roughly 4.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 139 days, looser than FY21's 72.
The full loop: cash goes out to suppliers and production on day 0; stock waits 129 days to sell; customers pay about 121 days after that; and suppliers themselves are paid at 111 days — netting out to the 139-day cycle.
In money terms: at FY26 sales of ₹703 Cr, each day of the cycle holds about ₹1.9 Cr — so the 139-day loop keeps roughly ₹268 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹94.0 Cr over the last 3 fiscal years against ₹7.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹3.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 15%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Sudarshan Pharma Industries Ltd earns a ROCE of 15% in FY26. That is up from a trough of 14% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 3.3% net margin on 1.10× asset turns.
FY26 ROCE is 15%, recovered from a FY24 trough of 14% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 3.3% net margin × 1.10× asset turns × 4.14× balance-sheet leverage ≈ 15.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 1.84.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Sudarshan Pharma Industries Ltd carries ₹285 Cr of borrowings against ₹155 Cr of equity in FY26, a debt-to-equity of 1.84. Operating profit covers the interest bill 2×. Over 5 years borrowings went from ₹30.0 Cr to ₹285 Cr. Capital spending ran ₹94.0 Cr across the last 3 of those years.
FY26: borrowings of ₹285 Cr against equity of ₹155 Cr — a debt-to-equity of 1.84. Operating profit covers the interest bill 2×. Over 5 years borrowings went from ₹30.0 Cr to ₹285 Cr while capital spending ran ₹94.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
→ Who owns this, and are they adding or leaving? Next: Foreign institutions added 18.0 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 18.0 points of Sudarshan Pharma Industries Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 19.4% of the company. Promoters moved +1.5 points over the same window, to 58.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +18.0 points over 8 quarters to 19.4%; Promoters: +1.5 points over 8 quarters to 58.9%.
Why the register moved: foreign institutions drove it (+18.0 points), alongside promoters (+1.5 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Sudarshan Pharma Industries Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Sudarshan Pharma Industries Ltd this page | 43.2× | ₹1,006 Cr | No read | |||
| Adani Enterprises Ltd | — | ₹4.1L Cr | Mixed | |||
| Lloyds Enterprises Ltd | 1,079.0× | ₹11,894 Cr | Turning around | |||
| RRP Semiconductor Ltd | — | ₹11,877 Cr | No read | |||
| MMTC Ltd | 92.2× | ₹9,228 Cr | No read | |||
| SG Mart Ltd | 72.3× | ₹8,993 Cr | Mixed | |||
| Rashi Peripherals Ltd | 18.5× | ₹5,139 Cr | Consistent | |||
| PTC India Ltd | 8.0× | ₹4,866 Cr | Mixed | |||
| Euro Pratik Sales Ltd | 37.2× | ₹3,083 Cr | No read | |||
| Shankara Buildpro Ltd | 23.1× | ₹2,998 Cr | No read | |||
| Blue Pearl Agriventures Ltd | 5,705.0× | ₹2,795 Cr | No read | |||
| BN Agrochem Ltd | 78.2× | ₹2,688 Cr | No read | |||
| Onix Solar Energy Ltd | 34.7× | ₹2,300 Cr | No read | |||
| Aayush Art and Bullion Ltd | 227.0× | ₹1,790 Cr | No read | |||
| Onix Solar Energy Ltd | 117.0× | ₹1,779 Cr | No read | |||
| Kothari Industrial Corporation Ltd | — | ₹1,761 Cr | No read | |||
| Kothari Industrial Corporation Ltd | — | ₹1,728 Cr | No read | |||
| Aayush Art and Bullion Ltd | 882.0× | ₹1,702 Cr | Mixed | |||
| Keto Motors Ltd | — | ₹1,603 Cr | No read | |||
| Le Merite Exports Ltd | 87.0× | ₹1,177 Cr | — | — | — | — |
| Arisinfra Solutions Ltd | 18.5× | ₹1,007 Cr | No read | |||
| Tembo Global Industries Ltd | 10.8× | ₹984 Cr | Mixed | |||
| A-1 Ltd | 383.0× | ₹947 Cr | Deteriorating | |||
| Bizotic Commercial Ltd | 86.4× | ₹936 Cr | — | — | — | — |
| Neueon Corporation Ltd | — | ₹930 Cr | No read | |||
| Shah Foods Ltd | 276.0× | ₹908 Cr | — | — | — | — |
| Hexa Tradex Ltd | — | ₹857 Cr | No read | |||
| Dhunseri Ventures Ltd | 9.4× | ₹854 Cr | Deteriorating | |||
| Vision Infra Equipment Solutions Ltd | 24.9× | ₹774 Cr | — | — | — | — |
| Hardwyn India Ltd | 58.5× | ₹773 Cr | Improving | |||
| Yogi Ltd | 36.9× | ₹765 Cr | No read | |||
| Patel Retail Ltd | 19.1× | ₹746 Cr | No read | |||
| Yogi Ltd | 39.1× | ₹741 Cr | No read | |||
| Nupur Recyclers Ltd | 51.0× | ₹725 Cr | Mixed | |||
| Mardia Samyoung Capillary Tubes Company Ltd | 687.0× | ₹707 Cr | No read | |||
| State Trading Corporation of India Ltd | 15.9× | ₹707 Cr | No read | |||
| Uniphos Enterprises Ltd | 33.0× | ₹683 Cr | No read | |||
| Cropster Agro Ltd | 43.7× | ₹679 Cr | No read | |||
| Fabtech Technologies Ltd | 13.7× | ₹666 Cr | No read | |||
| Sudarshan Pharma Industries Ltd | 28.7× | ₹609 Cr | No read |
Frequently asked questions
What is Sudarshan Pharma Industries Ltd's share price today?
Sudarshan Pharma Industries Ltd trades at ₹40.0, +37.8% over the past year. The company is valued at ₹1,006 Cr. The stock sits at 100% of its 52-week range of ₹20–₹40, +30.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 12 weeks in. — as of 24 July 2026.
What were Sudarshan Pharma Industries Ltd's latest quarterly results?
Sudarshan Pharma Industries Ltd reported revenue of ₹221 Cr and net profit of ₹11.0 Cr for the Mar 26 quarter. Revenue rose 36.4% and profit rose 57.1% year on year. Earnings per share were ₹0.45. The operating margin was 9.0%, 1.0 pp lower than a year earlier. — as of 24 July 2026.
What is Sudarshan Pharma Industries Ltd's revenue?
Sudarshan Pharma Industries Ltd reported revenue of ₹221 Cr in the Mar 26 quarter, +36.4% year on year. For the full FY26 fiscal year, revenue was ₹703 Cr (+39.2%). Over the last 6 years revenue compounded at 29.7% a year. — as of 24 July 2026.
What is Sudarshan Pharma Industries Ltd's profit?
Sudarshan Pharma Industries Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, +57.1% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹23.0 Cr. The operating margin ran 9.0% in the latest quarter. — as of 24 July 2026.
What is Sudarshan Pharma Industries Ltd's market cap?
Sudarshan Pharma Industries Ltd's market capitalisation is ₹1,006 Cr at a share price of ₹40.0. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Sudarshan Pharma Industries Ltd's P/E ratio?
Sudarshan Pharma Industries Ltd trades at a P/E of 43.2×, at the 77th percentile of its own 3-year range, against a long-run median of 31.2×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Sudarshan Pharma Industries Ltd pay a dividend?
Not in its latest year — Sudarshan Pharma Industries Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 1 of its last 7 reported fiscal years, so there is a history but no current dividend. — as of 24 July 2026.
Is Sudarshan Pharma Industries Ltd overvalued?
On its own history, Sudarshan Pharma Industries Ltd looks expensive against its own history: its P/E of 43.2× sits at the 77th percentile of its 3-year range (long-run median 31.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Sudarshan Pharma Industries Ltd growing?
Yes — Sudarshan Pharma Industries Ltd is growing: latest-quarter revenue +36.4% year on year, profit +57.1%, and the margin −1.0 pp at 9.0%. The 6-year compound rates are 29.7% (revenue) and 68.6% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Sudarshan Pharma Industries Ltd performing?
Sudarshan Pharma Industries Ltd is in a confirmed uptrend, 12 weeks in. Its latest quarter's revenue rose 36.4% and profit rose 57.1% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 25 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
Is Sudarshan Pharma Industries Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 12 of stage 2), trading +30.1% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Sudarshan Pharma Industries Ltd beating the market?
On recent form, yes — Sudarshan Pharma Industries Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 25 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 3.3 years the stock moved +539% against the NIFTY 500's +63% — ahead of the index over the full window. — as of 24 July 2026.
Will Sudarshan Pharma Industries Ltd's share price go up?
This page publishes no price forecast for Sudarshan Pharma Industries Ltd. What it measures instead: the share price is ₹40.0, the price is in a confirmed uptrend 12 weeks in. Its P/E of 43.2× sits at the 77th percentile of its own 3-year range. — as of 24 July 2026.
Who owns Sudarshan Pharma Industries Ltd?
Promoters hold 58.9% of Sudarshan Pharma Industries Ltd, foreign institutions 19.4%, domestic institutions null% and the public 21.6% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 18.0 points over 8 quarters. — as of 24 July 2026.
Does Sudarshan Pharma Industries Ltd have too much debt?
It carries real leverage — Sudarshan Pharma Industries Ltd's debt-to-equity is 1.84, and operating profit covers the interest bill 2×. FY26 borrowings were ₹285 Cr against equity of ₹155 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Sudarshan Pharma Industries Ltd's capex?
Sudarshan Pharma Industries Ltd spent ₹94.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹81.0 Cr, with ₹3.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Sudarshan Pharma Industries Ltd's cash flow?
Sudarshan Pharma Industries Ltd generated ₹−2.0 Cr of operating cash flow in FY26 and ₹−83.0 Cr of free cash flow after ₹81.0 Cr of capital spending. Reported profit that year was ₹23.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Sudarshan Pharma Industries Ltd's profit real cash?
Mostly — over the last 3 fiscal years, 78% of Sudarshan Pharma Industries Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−2.0 Cr against reported profit of ₹23.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 24 July 2026.
Where is Sudarshan Pharma Industries Ltd in its business cycle?
Sudarshan Pharma Industries Ltd's FY26 operating margin was 7.0%, against a 7-year band of 3.0%–8.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 9.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Sudarshan Pharma Industries Ltd story?
Biggest watch item: the P/E sits at the 77th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Sudarshan Pharma Industries Ltd a stock worth studying right now?
This is not investment advice. The machine read: Sudarshan Pharma Industries Ltd's earnings have outrun its stock. EPS grew +47.0% in a year against a +37.8% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.